Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial

Rob A Vergeer, Mark R Postma, Iris Schmidt, Astrid Gw Korsten-Meijer, Robert A Feijen, Schelto Kruijff, Wouter B Nagengast, J Marc C van Dijk, Wilfred F A den Dunnen, André P van Beek, Jos M A Kuijlen, Gerrit van den Berg, Rob A Vergeer, Mark R Postma, Iris Schmidt, Astrid Gw Korsten-Meijer, Robert A Feijen, Schelto Kruijff, Wouter B Nagengast, J Marc C van Dijk, Wilfred F A den Dunnen, André P van Beek, Jos M A Kuijlen, Gerrit van den Berg

Abstract

Introduction: Achieving gross total resection and endocrine remission in pituitary neuroendocrine tumours (PitNET) can be challenging, especially in PitNETs with cavernous sinus (CS) invasion, defined as a Knosp grade of 3 or 4. A potential target to identify PitNET tissue is vascular endothelial growth factor A (VEGF-A), which expression is known to be significantly higher in PitNETs with CS invasion.

Methods and analysis: The aim of this non-randomised, non-blinded, single centre, feasibility and dose-finding phase 1 trial is to determine the feasibility of intraoperative fluorescence imaging detection of PitNET tissue during endoscopic transsphenoidal surgery using the VEGF-A targeting optical agent bevacizumab-800CW (4, 5, 10 or 25 mg). Nine to fifteen patients with a PitNET with a Knosp grade of 3 or 4 will be included. Secondary objectives are: (1) To identify the optimal tracer dose for imaging of PitNET tissue during transsphenoidal surgery for further development in a phase 2 fluorescence molecular endoscopy trial. (2) To quantify fluorescence intensity in vivo and ex vivo with multidiameter single-fibre reflectance, single-fibre fluorescence (MDSFR/SFF) spectroscopy. (3) To correlate and validate both the in vivo and ex vivo measured fluorescence signals with histopathological analysis and immunohistochemical staining. (4) To assess the (sub)cellular location of bevacizumab-800CW by ex vivo fluorescence microscopy. Intraoperative, three imaging moments are defined to detect the fluorescent signal. The tumour-to-background ratios are defined by intraoperative fluorescence in vivo measurements including MDSFR/SFF spectroscopy data and by ex vivo back-table fluorescence imaging. After inclusion of three patients in each dose group, an interim analysis will be performed to define the optimal dose.

Ethics and dissemination: Approval was obtained from the Medical Ethics Review Board of the University Medical Centre Groningen. Results will be disseminated through national and international journals. The participants and relevant patient support groups will be informed about the results.

Trial registration number: NCT04212793.

Keywords: neurosurgery; pituitary disorders.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flowchart.

References

    1. Aflorei ED, Korbonits M. Epidemiology and etiopathogenesis of pituitary adenomas. J Neurooncol 2014;117:379–94. 10.1007/s11060-013-1354-5
    1. Sherlock M, Ayuk J, Tomlinson JW, et al. . Mortality in patients with pituitary disease. Endocr Rev 2010;31:301–42. 10.1210/er.2009-0033
    1. Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA 2017;317:516–24. 10.1001/jama.2016.19699
    1. Knosp E, Steiner E, Kitz K, et al. . Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993;33:610–7. 10.1227/00006123-199310000-00008
    1. Micko ASG, Wöhrer A, Wolfsberger S, et al. . Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 2015;122:803–11. 10.3171/2014.12.JNS141083
    1. Buchy M, Lapras V, Rabilloud M, et al. . Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification. Pituitary 2019;22:467–75. 10.1007/s11102-019-00976-6
    1. Biermasz NR, Roelfsema F, Pereira AM, et al. . Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res 2009;9:223–34. 10.1586/erp.09.17
    1. Chang SW, Donoho DA, Zada G. Use of optical fluorescence agents during surgery for pituitary adenomas: current state of the field. J Neurooncol 2019;141:585–93. 10.1007/s11060-018-03062-2
    1. van Leeuwen-van Zaane F, Gamm UA, van Driel PBAA, et al. . In vivo quantification of the scattering properties of tissue using multi-diameter single fiber reflectance spectroscopy. Biomed Opt Express 2013;4:696–13. 10.1364/BOE.4.000696
    1. Hoy CL, Gamm UA, Sterenborg HJCM, et al. . Method for rapid multidiameter single-fiber reflectance and fluorescence spectroscopy through a fiber bundle. J Biomed Opt 2013;18:107005. 10.1117/1.JBO.18.10.107005
    1. Middelburg TA, Hoy CL, Neumann HAM, et al. . Correction for tissue optical properties enables quantitative skin fluorescence measurements using multi-diameter single fiber reflectance spectroscopy. J Dermatol Sci 2015;79:64–73. 10.1016/j.jdermsci.2015.03.017
    1. Iuchi T, Saeki N, Osato K, et al. . Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir 2000;142:1345–51. 10.1007/s007010070003
    1. Kim KJ, Li B, Winer J, et al. . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841–4. 10.1038/362841a0
    1. Niveiro M, Aranda FI, Peiró G, et al. . Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. Hum Pathol 2005;36:1090–5. 10.1016/j.humpath.2005.07.015
    1. Cristina C, Perez-Millan MI, Luque G, et al. . VEGF and CD31 association in pituitary adenomas. Endocr Pathol 2010;21:154–60. 10.1007/s12022-010-9119-6
    1. Trouillas J, Delgrange E, Wierinckx A, et al. . Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours. Neuroendocrinology 2019;109:70–6. 10.1159/000499382
    1. Wang Y, Li J, Tohti M, et al. . The expression profile of dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy. J Exp Clin Cancer Res 2014;33:56. 10.1186/s13046-014-0056-y
    1. Wierinckx A, Delgrange E, Bertolino P, et al. . Sex-related differences in lactotroph tumor aggressiveness are associated with a specific gene-expression signature and genome instability. Front Endocrinol 2018;9:706. 10.3389/fendo.2018.00706
    1. Lloyd RV, Scheithauer BW, Kuroki T, et al. . Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 1999;10:229–35. 10.1007/BF02738884
    1. Marshall MV, Draney D, Sevick-Muraca EM, et al. . Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol Imaging Biol 2010;12:583–94. 10.1007/s11307-010-0317-x
    1. Ter Weele EJ, Terwisscha van Scheltinga AGT, Linssen MD, et al. . Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use. Eur J Pharm Biopharm 2016;104:226–34. 10.1016/j.ejpb.2016.05.008

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj